KEYNOTE-185, 2018 trial summary

A randomised clinical trial investigating the effect of pembrolizumab, lenalidomide, dexametahsone versus lenalidomide, dexamethasone in newly diagnosed and treatment naïve Multiple Myeloma who are ineligible for autologous stem cell transplant

        Z

NCT02579863    



Studied treatment
pembrolizumab, lenalidomide and low-dose dexamethasone
Control treatment lenalidomide and low-dose dexamethasone



Patients newly diagnosed and treatment naïve Multiple Myeloma who are ineligible for autologous stem cell transplant
Group sizes151 / 150

Only 301 of the 640 planned had been enrolled when the trial was halted



Blindness open-design Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design Parallel groups



EndpointX1N1X0N0TE95% CI OS - 151 - 150 no data PFS - 151 - 150 no data0,22,01,0

Links

news

ClinicalTrial.gov record NCT02579863



Registering number NCT02579863 (see trial on clinicaltrials.gov)
Code Name